PMID- 12633119
OWN - NLM
STAT- MEDLINE
DCOM- 20030326
LR  - 20190901
IS  - 0160-6689 (Print)
IS  - 0160-6689 (Linking)
VI  - 64
IP  - 2
DP  - 2003 Feb
TI  - Switching from depot antipsychotic drugs to olanzapine in patients with chronic 
      schizophrenia.
PG  - 119-22
AB  - BACKGROUND: Patients with chronic schizophrenia (DSM-IV criteria) often receive 
      depot antipsychotic medications to assure longer administration and better 
      compliance with their treatment regimen. This study evaluated whether patients 
      stabilized on depot antipsychotic medication could be successfully transitioned 
      to oral olanzapine. METHOD: In a 3-month open-label study, 26 clinically stable 
      patients with schizophrenia taking depot antipsychotics for over 3 years were 
      randomly assigned to continue on their current depot dose or to switch to oral 
      olanzapine. Clinical ratings (Positive and Negative Syndrome Scale [PANSS], 
      Global Assessment of Functioning [GAF] scale, and Clinical Global Impressions 
      [CGI] scale) and side effect parameters (Abnormal Involuntary Movement Scale 
      [AIMS], Barnes Akathisia Scale, AMDP-5 scale, vital signs, and weight) were 
      obtained monthly. RESULTS: Oral olanzapine patients (N = 13) demonstrated 
      significant clinical improvement over the depot control group (N = 13) from 
      baseline to 3-month endpoint (PANSS total, p =.012; PANSS general, p =.068; PANSS 
      negative, p =.098; CGI-Improvement, p =.007; CGI-Severity, p =.026; GAF, p 
      =.015). Side effect rating scales showed no statistical differences between the 2 
      groups (AIMS, Barnes Akathisia Scale, AMDP-5, vital signs). The depot control 
      group showed no statistical superiority in any measure except weight change (p 
      =.0005). After 3 months, all olanzapine patients preferred olanzapine to their 
      previous depot medications and chose to continue on olanzapine treatment. 
      CONCLUSION: Clinicians may expect clinical improvement when switching chronically 
      psychotic patients from traditional depot antipsychotic drugs to oral olanzapine. 
      Switching may be completed within a 4-week period with relative compliance being 
      maintained and patients preferring oral olanzapine to their previous depot 
      medications.
FAU - Godleski, Linda S
AU  - Godleski LS
AD  - Department of Veterans Affairs Medical Center, Louisville, Ky, USA. 
      Linda.Godleski@med.va.gov
FAU - Goldsmith, L Jane
AU  - Goldsmith LJ
FAU - Vieweg, W Victor
AU  - Vieweg WV
FAU - Zettwoch, Nancy C
AU  - Zettwoch NC
FAU - Stikovac, Dejzi M
AU  - Stikovac DM
FAU - Lewis, Susan J
AU  - Lewis SJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Psychiatry
JT  - The Journal of clinical psychiatry
JID - 7801243
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 3G0285N20N (Pirenzepine)
RN  - J60AR2IKIC (Clozapine)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antipsychotic Agents/*administration & dosage/therapeutic use
MH  - Benzodiazepines
MH  - Chronic Disease
MH  - Clozapine/administration & dosage
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Olanzapine
MH  - Patient Compliance/psychology
MH  - Pirenzepine/*administration & dosage/*analogs & derivatives/therapeutic use
MH  - Psychiatric Status Rating Scales
MH  - Schizophrenia/diagnosis/*drug therapy
MH  - Schizophrenic Psychology
MH  - Treatment Outcome
EDAT- 2003/03/14 04:00
MHDA- 2003/03/27 05:00
CRDT- 2003/03/14 04:00
PHST- 2003/03/14 04:00 [pubmed]
PHST- 2003/03/27 05:00 [medline]
PHST- 2003/03/14 04:00 [entrez]
AID - 10.4088/jcp.v64n0203 [doi]
PST - ppublish
SO  - J Clin Psychiatry. 2003 Feb;64(2):119-22. doi: 10.4088/jcp.v64n0203.